What the Research Says
Selenium has one of the strongest evidence bases among minerals for thyroid support. The landmark Gartner et al. (2002) RCT demonstrated a 21% reduction in TPO antibodies with 200mcg selenomethionine daily in Hashimoto's patients. The EUGOGO trial (Marcocci et al., 2011, NEJM) showed selenium improved outcomes in mild Graves' orbitopathy. Negro et al. (2007) demonstrated reduced postpartum thyroiditis in TPO-antibody-positive pregnant women. A 2010 Cochrane review acknowledged the evidence but called for larger, longer trials to confirm clinical endpoints beyond antibody reduction.
